# Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

> **NCT00478218** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 53 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** dexamethasone
- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT00478218
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-09
- **Final completion:** 2011-04
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2011-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00478218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00478218, "Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00478218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*